Cargando…

COVID-19: What Do Rheumatologists Need to Know?

PURPOSE OF REVIEW: Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) emerged in December 2019, rapidly reaching global pandemic proportions. Coronavirus disease 2019 (COVID-19) has presented unique challenges to the rheumatology community. It is known that many individuals with rh...

Descripción completa

Detalles Bibliográficos
Autores principales: Fitzgerald, Gillian E., Maguire, Sinead, Haroon, Nigil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785126/
https://www.ncbi.nlm.nih.gov/pubmed/33403528
http://dx.doi.org/10.1007/s11926-020-00971-y
_version_ 1783632391824211968
author Fitzgerald, Gillian E.
Maguire, Sinead
Haroon, Nigil
author_facet Fitzgerald, Gillian E.
Maguire, Sinead
Haroon, Nigil
author_sort Fitzgerald, Gillian E.
collection PubMed
description PURPOSE OF REVIEW: Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) emerged in December 2019, rapidly reaching global pandemic proportions. Coronavirus disease 2019 (COVID-19) has presented unique challenges to the rheumatology community. It is known that many individuals with rheumatic disease are at increased risk of severe disease from other infections, sparking a similar fear for COVID-19. In addition, medications routinely used in rheumatology practice are being trialled as treatments, with the potential for drug shortages for rheumatology patients. RECENT FINDINGS: Underlying comorbidities and active disease are associated with worse COVID-19 outcomes in patients with rheumatic disease. Tocilizumab and hydroxychloroquine have not proven to be effective treatments in the management of COVID-19. Telehealth has become an essential tool for the rheumatology community to monitor patients during the pandemic. SUMMARY: In this article, we summarise the available COVID-19 evidence that is of relevance to the rheumatology community. We discuss the risk of contracting COVID-19 in individuals with rheumatic disease, along with presenting features and clinical outcomes. We provide an overview of the treatments for COVID-19 which have significance for rheumatology. We highlight published recommendations which can guide our management of rheumatic disease populations during this pandemic. Finally, we discuss the challenges in delivering effective care virtually and present methods and tools which could be adapted for use.
format Online
Article
Text
id pubmed-7785126
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-77851262021-01-06 COVID-19: What Do Rheumatologists Need to Know? Fitzgerald, Gillian E. Maguire, Sinead Haroon, Nigil Curr Rheumatol Rep Spondyloarthritis (M Khan, Section Editor) PURPOSE OF REVIEW: Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) emerged in December 2019, rapidly reaching global pandemic proportions. Coronavirus disease 2019 (COVID-19) has presented unique challenges to the rheumatology community. It is known that many individuals with rheumatic disease are at increased risk of severe disease from other infections, sparking a similar fear for COVID-19. In addition, medications routinely used in rheumatology practice are being trialled as treatments, with the potential for drug shortages for rheumatology patients. RECENT FINDINGS: Underlying comorbidities and active disease are associated with worse COVID-19 outcomes in patients with rheumatic disease. Tocilizumab and hydroxychloroquine have not proven to be effective treatments in the management of COVID-19. Telehealth has become an essential tool for the rheumatology community to monitor patients during the pandemic. SUMMARY: In this article, we summarise the available COVID-19 evidence that is of relevance to the rheumatology community. We discuss the risk of contracting COVID-19 in individuals with rheumatic disease, along with presenting features and clinical outcomes. We provide an overview of the treatments for COVID-19 which have significance for rheumatology. We highlight published recommendations which can guide our management of rheumatic disease populations during this pandemic. Finally, we discuss the challenges in delivering effective care virtually and present methods and tools which could be adapted for use. Springer US 2021-01-05 2021 /pmc/articles/PMC7785126/ /pubmed/33403528 http://dx.doi.org/10.1007/s11926-020-00971-y Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Spondyloarthritis (M Khan, Section Editor)
Fitzgerald, Gillian E.
Maguire, Sinead
Haroon, Nigil
COVID-19: What Do Rheumatologists Need to Know?
title COVID-19: What Do Rheumatologists Need to Know?
title_full COVID-19: What Do Rheumatologists Need to Know?
title_fullStr COVID-19: What Do Rheumatologists Need to Know?
title_full_unstemmed COVID-19: What Do Rheumatologists Need to Know?
title_short COVID-19: What Do Rheumatologists Need to Know?
title_sort covid-19: what do rheumatologists need to know?
topic Spondyloarthritis (M Khan, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785126/
https://www.ncbi.nlm.nih.gov/pubmed/33403528
http://dx.doi.org/10.1007/s11926-020-00971-y
work_keys_str_mv AT fitzgeraldgilliane covid19whatdorheumatologistsneedtoknow
AT maguiresinead covid19whatdorheumatologistsneedtoknow
AT haroonnigil covid19whatdorheumatologistsneedtoknow